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Abstract
A leucine analog containing a ketone has been incorporated into proteins in E. coli. Only E. coli
strains overexpressing an editing-deficient leucyl-tRNA synthetase were capable of synthesizing
proteins with the aliphatic ketone amino acid. Modification of ketone-containing proteins under
mild conditions has been demonstrated.
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Relaxing the substrate specificity of the aminoacyl-tRNA synthetases (aaRSs) allows in vivo
incorporation of non-canonical amino acids into recombinant proteins. We and others have
demonstrated that impairing the proofreading activities of Class I aaRSs enables the E. coli
translational machinery to insert amino acids that are normally edited following tRNA
aminoacylation.[1–7] Furthermore, recent work has shown that manipulating aaRSs by
altering editing activity[8] or by transplanting editing domains[9] can improve the fidelity
with which non-canonical amino acids are incorporated into proteins. We reported
previously that an E. coli leucyl-tRNA synthetase (LeuRS) carrying the mutation T252Y, a
residue critical in modulating the editing site geometry,[2, 3, 10] is unable to proofread amino
acids with unbranched side chains, and enables insertion of a variety of non-canonical amino
acids into recombinant proteins in place of leucine (1).[1] In this report, we demonstrate
further application of this mutant to effect residue-specific incorporation of oxonorvaline
(3). Introduction of the aliphatic ketone group of 3 allows chemoselective modification of
proteins under mild conditions.
We first tested the translational activities of 3 and its hydrocarbon isostere didehydroleucine
(2) in a leucine-auxotrophic E. coli host strain (LAM1000/pA1EL/pREP4) that
overexpresses wild-type LeuRS. The target protein was a hexahistidine-tagged synthetic
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leucine zipper designated A1, the properties of which have been discussed previously.[11] As
shown in Figure 1A, 2 supported protein expression at a level comparable to that observed
in cultures supplemented with 1, whereas 3 did not. We determined the rates of activation of
2 and 3 by LeuRS by means of the ATP-PPi exchange assay (Table 1).[1] The specificity
constant kcat/Km for the alkenyl substrate 2 is reduced approximately 100-fold compared to
1, while that of 3 is reduced 4500-fold. The lower activation rate, however, is not sufficient
to rationalize the lack of translational activity of 3. We have previously described the
efficient incorporation of hexafluoroleucine (Hfl) into recombinant proteins expressed in E.
coli LAM1000/pA1EL/pREP4, despite the fact that the specificity constant for Hfl is nearly
equal to that for 3 (kcat/Km (rel) of LeuRS for Hfl: 1/4100).[11] We therefore hypothesized
that the lack of incorporation of 3 was attributable to the editing activity of wild-type
LeuRS. Consistent with this conjecture, we found that a host strain (E. coli LAM1000/
pA1T252Y/pREP4) outfitted with the T252Y LeuRS mutant afforded good yields of A1 in
M9 medium depleted of leucine, isoleucine, valine, and methonine (M9 –LIVM medium)[1]
and supplemented with 3 (Figure 1A, lane viii). The electrophoretic mobility of the
substituted protein was reduced, an effect observed previously in variants of A1 containing
leucine surrogates.[1] The purified protein from this sample was characterized by a molar
mass indistinguishable (by MALDI mass spectometry, Figure 1B) from that of the leucine
form of the protein (1-A1), since the masses of 1 and 3 are nearly identical.
To confirm incorporation of 3, we treated tryptic fragments of A1 samples containing 1, 2 or
3, with hydroxylamine (1 mM) for two hours at room temperature. As indicated in Figures
2A and 2B, fragments containing 1 and 2 were not modified. The same fragment (which
contains three residues encoded as leucine) derived from the protein containing 3 (3-A1)
yielded a ladder of signals (Figure 2C) in which each 15-unit mass shift indicates
replacement of 1 by 3 and subsequent conversion of the ketone side chain to the oxime.
Amino acid analysis indicated approximately 60% replacement of 1 by 3; the heterogeneity
arising from partial substitution is the most likely source of band-broadening in lane viii of
Figure 1A. Modification of the protein by hydrazide reagents was also demonstrated.
Samples of 1-A1 and 3-A1 were treated with biotin hydrazide, subjected to western blot
analysis and visualized with a biotin-specific streptavidin-HRP conjugate. The reaction is
specific for 3-A1 (Figure 2D, lane iv).
These results show that incorporation of oxonorvaline into recombinant proteins requires an
expression strain outfitted with an editing-attenuated form of LeuRS. But proofreading of 3
by the wild-type LeuRS is somewhat surprising. Previous studies have suggested that amino
acids (including 1) branched at the γ-carbon are sterically excluded from the LeuRS editing
cavity, at least in part by the gatekeeping residue T252.[2, 3, 5, 10] Why should 3 be edited
when its isostere 2 is not? The explanation may lie in the hydrogen-bond acceptor character
of the ketone function. Previous work has demonstrated that wild-type E. coli LeuRS edits
exclusively through a posttransfer mechanism.[12, 13] Therefore, after the enzymatic ligation
of 3 and tRNALeu in the aminoacylation active site, the 3’ end of newly formed 3-tRNALeu
changes conformations to allow 3 to enter the posttransfer editing active site of LeuRS. If 3
forms a hydrogen bond with one or more residues in the editing site, it may be subjected to
hydrolytic cleavage from tRNALeu.
To test this hypothesis, we generated two additional mutants (T252I and T252V) of LeuRS.
The four LeuRS variants examined here are characterized by residue volumes (at position
252) of 194 (Y), 167 (I), 140 (V) and 116 (T) Å3, respectively.[14] An ordered water
molecule appears within 2.83 Å of residue T252 in a crystal structure of LeuRS determined
in the absence of ligand.[15] If one estimates the effective side-chain volume of residue 252
of the wild-type synthetase by adding the molar volume of water (30 Å3), the wild-type and
T252V variants would be expected to form editing cavities roughly equal in size (assuming
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that the water molecule is displaced in T252V). We examined the capacity of each of the
four synthetase variants to incorporate 1, 3, and norvaline (4) (a known substrate of the wild-
type LeuRS editing site), into proteins. As expected, cells harboring each of the four variants
were able to synthesize full-length protein in M9 –LIVM medium supplemented with the
natural substrate leucine (Figure 3, lanes i–iv). Supplementing the expression medium with
norvaline leads to expression of full-length protein only when bulkier amino acids (Y and I)
are substituted at position 252 (Figure 3, lanes v–viii); 4 is edited both by the wild-type
synthetase and by the T252V mutant. In contrast, 3 supports protein synthesis in M9 –LIVM
medium when the threonine residue at position 252 is mutated to valine, isoleucine, or
tyrosine (Figure 3, lanes ix–xii). Even introducing the subtle T252V mutation, in which the
side-chain hydroxyl group of residue T252 is replaced by a methyl group, yields an
expression system in which 3 is translationally active. We suggest that the most plausible
explanation of these results involves anchoring of 3 in the editing cavity of the wild-type
enzyme through formation of a hydrogen bond to the side-chain hydroxyl group of T252.
Because 2 forms no such hydrogen bond, it is excluded from the editing site of the wild-type
synthetase and is translationally active in wild-type cells. Removal of the hydrogen-bond
donor site through introduction of the T252V mutation reduces the affinity of 3 for the
editing site and allows 3 to escape proofreading by the synthetase. An analogous mechanism
has been proposed by Fersht to describe the editing specificity of valyl-tRNA synthetase
toward threonine.[16]
In conclusion, we report successful incorporation of oxonorvaline into recombinant proteins
through redesign of the editing domain of the E. coli leucyl-tRNA synthetase. The selective
chemistry of the oxonorvaline side chain promises to provide useful new approaches to
protein engineering and proteomic analysis.[17–19]
Experimental Section
Detailed experimental protocols can be found in the supporting information.
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Figure 1.
Incorporation of 2 and 3 into target protein A1. A) Coomassie Brilliant Blue-stained SDS-
PAGE gels of whole cell lysates after expressions in M9 –LIVM medium. Lanes i–iv:
expression in host LAM1000/pA1EL/pREP4. Lanes v–viii: expression in host LAM1000/
pA1T252Y/pREP4. Lanes i and v: induction without 1; lanes ii and vi: Induction with 1 at
40 mg L−1; lanes iii and vii: induction with 2 at 100 mg L−1; lanes iv and viii: induction
with 3 at 200 mg L−1. All concentrations are of the L-isomer. B) MALDI-MS of protein
shown in lane viii. The single peak (found: 8307 Da; calculated: 8307 Da) confirms the
identity of the protein.
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Figure 2.
Chemoselective modification of the ketone moiety in target protein A1. A)–C) Mass spectra
of the tryptic fragment LKNEIEDLKAEIGDLNNTSGIR derived from A1; A) 1-A1 (found:
2442 Da; calculated: 2442 Da); B) 2-A1 (found: 2436 Da; calculated: 2436 Da); C) 3-A1
(found: 2442 Da; calculated: 2442 Da). Before hydroxylamine treatment, the mass of 3-A1
is nearly identical to that of 1-A1. After treatment with hydroxylamine (1 mM) in PBS (pH
6.5) for two hours at room temperature, mass peaks separated by 15 mass units were
observed, corresponding to the conversion from ketone to oxime. Fragments shown in A)
and B) were unmodified after treatment. D) Biotin-specific western blot analyses of 1-A1
and 3-A1 treated with biotin-hydrazide. Lane i: 1-A1 before treatment; ii: 3-A1 before
treatment; iii: 1-A1 after treatment; iv: 3-A1 after treatment.
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Figure 3.
SDS-PAGE analysis of protein expression in cells overexpressing editing mutants of LeuRS.
Expression in M9 –LIVM medium supplemented with 1, 3, or 4, was performed with E. coli
cells overexpressing LeuRS containing Y, I, V, or T at position 252. After expression, whole
cell lysates were subjected to SDS-PAGE, and proteins were visualized with Coomassie
Brilliant Blue stain.
Tang et al. Page 7
Chembiochem. Author manuscript; available in PMC 2011 October 3.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Scheme 1.
Amino acids used in this study. 1: leucine; 2: didehydroleucine; 3: oxonorvaline; 4:
norvaline.
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Table 1
Amino Acid Activation by Wild-type LeuRS.[a]
Substrate kcat (s−1) Km (µM)[b] kcat/Km (rel)
1[c] 2.2±0.02 18±1.7 1
2 1.08±0.12 1034±260 1/117
3 0.06±0.01 2245±804 1/4573
[a]
6xHis fusion protein.[1]
[b]
Concentration of L-isomer.
[c]
The kinetic parameters of the T252Y mutant were determined to be essentially the same as those for the wild-type enzyme for leucine (kcat =
1.92 ± 0.03 s−1, Km = 20 ± 2.3 μM).[1]
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